Cogent Biosciences, Inc.
Company Stats
- Market Cap
- $5.6B
- as of Sep 30, 2026
- Enterprise Value
- $5.5B
- Shares Outstanding
- 173.5M
- Free Float
- 83.1%
Income Statement
- Operating Income
- -$333.4M
- Net Income
- -$328.9M
- EBITDA
- -$330.8M
Cash Flow
- Free Cash Flow
- -$266.0M
- FCF Yield
- -4.8%
- Owner FCF Yield
- -5.6%
Balance Sheet
- Cash & Equivalents
- $312.0M
- Total Debt
- $230.0M
- Net Cash
- $82.0M
Returns & Capital
- SBC, 3Y Avg
- $38.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$266.0M | — |
| FY2024 | — | -$208.4M | — |
| FY2023 | — | -$156.4M | — |
| FY2022 | — | -$125.5M | — |
| FY2021 | — | -$60.5M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back